FORTIS HEALTHCARE LTD.

Fortis Healthcare Limited has announced the closure of its trading window for dealing in the company's shares. This closure will be effective from July 01, 2026, and will remain in effect until 48 hours after the declaration of the un-audited financial results for the quarter ending June 30, 2026. This measure is in compliance with the company's policy/code of conduct for the prevention of insider trading, ensuring fair market practices.

Fortis Hospitals Limited, a wholly-owned subsidiary of Fortis Healthcare Ltd, has successfully processed a rectification application with the Income Tax Authority. This has reduced the tax demand for AY 2024-25 from INR 117.04 Crores to INR 61.48 Crores. The original order was issued by the Income Tax Authority on June 3, 2026, under Section 154 read with Section 143(3) of the Income Tax Act, 1961. This significant reduction in tax liability is a positive development for the company's financial standing.

Fortis Healthcare has submitted a report from its Registrar and Share Transfer Agent, KFin Technologies Limited, detailing the status of re-lodgement requests for physical shares. For March 2026, 736 requests were received, all processed and rejected, with an average processing time of 6 days. For April 2026, no requests were received or processed. This disclosure is in compliance with SEBI circulars regarding a special window for re-lodging transfer requests.

Fortis Healthcare Ltd's board approved the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. The board recommended a final dividend of ₹1 per equity share (10% of face value of ₹10 each) for FY26, subject to shareholder approval. M/s Jitender, Navneet & Co. were appointed as Cost Auditor for FY 2026-27. The board also approved the Corporate Social Responsibility policy.

Fortis Healthcare Ltd's board approved the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. An unmodified audit opinion was issued by B S R & Co. LLP. The board recommended a final dividend of ₹1 per equity share (10% of face value of ₹10 each) for FY26, subject to shareholder approval. M/s Jitender, Navneet & Co. were appointed as Cost Auditor for FY 2026-27. The CSR policy was also approved.

Fortis Healthcare Ltd announced its Q4 FY26 and FY26 financial results. The board recommended a dividend of ₹1 per share. Consolidated revenues for FY26 stood at ₹9,128 Cr, up 17.3% YoY, with operating EBITDA up 31.3% to ₹2,085 Cr and a margin of 22.8%. Profit After Tax for FY26 increased by 31.5% to ₹1,064 Cr. The company's net debt as of March 31, 2026, was ₹2,334 Cr.

Fortis Healthcare Ltd has appointed M/s Jitender, Navneet & Co., Cost Accountants as the Cost Auditor for the financial year 2026-27. The appointment was approved during the Board of Directors meeting held on May 22, 2026. The company also approved the financial results for the quarter and financial year ended March 31, 2026, and recommended a final dividend of ₹ 1 per equity share.

Fortis Healthcare Ltd's board approved the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. An unmodified audit opinion was issued by B S R & Co. LLP. The board recommended a final dividend of ₹1 per equity share (10% of face value of ₹10 each) for FY26, subject to shareholder approval. M/s Jitender, Navneet & Co. were appointed as Cost Auditors for FY 2026-27. The company's CSR policy was also approved.

Fortis Healthcare Ltd's board approved the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. The board recommended a final dividend of ₹1 per equity share (10% of face value of ₹10 each) for FY26, subject to shareholder approval. M/s Jitender, Navneet & Co. were appointed as Cost Auditor for FY 2026-27. The board also approved the Corporate Social Responsibility policy.

Fortis Healthcare Ltd's board approved the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. The board also recommended a final dividend of ₹1 per equity share (10% of face value of ₹10 each) for the financial year 2025-26, subject to shareholder approval. M/s Jitender, Navneet & Co. were appointed as Cost Auditor for FY 2026-27.